7YNS
 
 | |
7YNG
 | |
7YNP
 | | BF227-bound alpha-synuclein fibrils | | Descriptor: | 5-[(~{E})-2-(6-methoxy-1,3-benzoxazol-2-yl)ethenyl]-~{N},~{N}-dimethyl-1,3-thiazol-2-amine, Alpha-synuclein | | Authors: | Tao, Y.Q, Zhao, Q.Y, Liu, C, Li, D. | | Deposit date: | 2022-07-31 | | Release date: | 2023-08-02 | | Method: | ELECTRON MICROSCOPY (2.8 Å) | | Cite: | BF227-bound alpha-synuclein fibrils
To Be Published
|
|
7YNL
 | | EB-bound alpha-synuclein fibrils | | Descriptor: | 4-azanyl-6-[[4-[4-[(~{E})-(8-azanyl-1-oxidanyl-5,7-disulfo-naphthalen-2-yl)diazenyl]-3-methyl-phenyl]-2-methyl-phenyl]diazenyl]-5-oxidanyl-naphthalene-1,3-disulfonic acid, Alpha-synuclein | | Authors: | Tao, Y.Q, Zhao, Q.Y, Liu, C, Li, D. | | Deposit date: | 2022-07-31 | | Release date: | 2023-08-02 | | Method: | ELECTRON MICROSCOPY (2.6 Å) | | Cite: | EB-bound alpha-synuclein fibrils
To Be Published
|
|
7YNT
 | |
7YNN
 | | ThT-bound alpha-synuclein fibrils conformation 2 | | Descriptor: | 2-[4-(dimethylamino)phenyl]-3,6-dimethyl-1,3-benzothiazol-3-ium, Alpha-synuclein | | Authors: | Tao, Y.Q, Zhao, Q.Y, Liu, C, Li, D. | | Deposit date: | 2022-07-31 | | Release date: | 2023-08-02 | | Method: | ELECTRON MICROSCOPY (2.9 Å) | | Cite: | ThT-bound alpha-synuclein fibrils conformation 2
To Be Published
|
|
7YNR
 | |
7YNQ
 | |
7YNF
 | | CCA-bound alpha-synuclein fibrils | | Descriptor: | Alpha-synuclein, copper;trisodium;18-(2-carboxylatoethyl)-20-(carboxylatomethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18-dihydroporphyrin-21,23-diide-2-carboxylate | | Authors: | Tao, Y.Q, Zhao, Q.Y, Liu, C, Li, D. | | Deposit date: | 2022-07-30 | | Release date: | 2023-12-06 | | Method: | ELECTRON MICROSCOPY (2.5 Å) | | Cite: | CCA-bound alpha-synuclein fibrils
To Be Published
|
|
6JKV
 | | PppA, a key regulatory component of T6SS in Pseudomonas aeruginosa | | Descriptor: | MANGANESE (II) ION, PppA | | Authors: | Wang, T, Liu, L, Wu, Y, Li, D. | | Deposit date: | 2019-03-02 | | Release date: | 2019-06-26 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (2.1 Å) | | Cite: | Crystal structure of PppA from Pseudomonas aeruginosa, a key regulatory component of type VI secretion systems.
Biochem.Biophys.Res.Commun., 516, 2019
|
|
6K3B
 | | Crystal structure of Lpg2147-Lpg2149 complex | | Descriptor: | Lpg2147, Uncharacterized protein | | Authors: | Mu, Y, Wang, Y, Han, Y, Li, D, Feng, Y. | | Deposit date: | 2019-05-17 | | Release date: | 2020-04-01 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (1.974 Å) | | Cite: | Structural insights into the mechanism and inhibition of transglutaminase-induced ubiquitination by the Legionella effector MavC.
Nat Commun, 11, 2020
|
|
6KFP
 | | Crystal structure of MavC ternary complex | | Descriptor: | MavC, Ubiquitin-40S ribosomal protein S27a, Ubiquitin-conjugating enzyme E2 N | | Authors: | Mu, Y, Wang, Y, Han, Y, Li, D, Feng, Y. | | Deposit date: | 2019-07-08 | | Release date: | 2020-04-01 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (2.92 Å) | | Cite: | Structural insights into the mechanism and inhibition of transglutaminase-induced ubiquitination by the Legionella effector MavC.
Nat Commun, 11, 2020
|
|
6LP2
 | | Structure of Lpg2148/UBE2N-Ub complex | | Descriptor: | Ubiquitin, Ubiquitin-conjugating enzyme E2 N, Uncharacterized protein lpg2148 | | Authors: | Feng, Y, Wang, Y, Huang, Y, Li, D. | | Deposit date: | 2020-01-08 | | Release date: | 2021-01-13 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (2.479 Å) | | Cite: | Structure of Lpg2148/UBE2N-Ub complex
To Be Published
|
|
6LW4
 | |
7WEK
 | |
7WEJ
 | | Crystal structure of the mouse Wdr47 NTD. | | Descriptor: | WD repeat-containing protein 47 | | Authors: | Ren, J.Q, Li, D, Feng, W. | | Deposit date: | 2021-12-23 | | Release date: | 2022-11-30 | | Method: | X-RAY DIFFRACTION (3.09 Å) | | Cite: | Intertwined Wdr47-NTD dimer recognizes a basic-helical motif in Camsap proteins for proper central-pair microtubule formation.
Cell Rep, 41, 2022
|
|
4WQ6
 | | The crystal structure of human Nicotinamide phosphoribosyltransferase (NAMPT) in complex with N-(4-{(S)-[1-(2-methylpropyl)piperidin-4-yl]sulfinyl}benzyl)furo[2,3-c]pyridine-2-carboxamide inhibitor (compound 21) | | Descriptor: | 1,2-ETHANEDIOL, N-(4-{(S)-[1-(2-methylpropyl)piperidin-4-yl]sulfinyl}benzyl)furo[2,3-c]pyridine-2-carboxamide, Nicotinamide phosphoribosyltransferase, ... | | Authors: | Li, D, Wang, W. | | Deposit date: | 2014-10-21 | | Release date: | 2015-02-11 | | Last modified: | 2023-09-27 | | Method: | X-RAY DIFFRACTION (1.72 Å) | | Cite: | Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.
Bioorg.Med.Chem.Lett., 25, 2015
|
|
7RRD
 | | IDO1 IN COMPLEX WITH COMPOUND S-1 | | Descriptor: | 3-[4-(1H-benzimidazol-2-yl)phenyl]-N-(4-fluorophenyl)oxetane-3-carboxamide, Indoleamine 2,3-dioxygenase 1 | | Authors: | Lesburg, C.A. | | Deposit date: | 2021-08-09 | | Release date: | 2022-08-24 | | Method: | X-RAY DIFFRACTION (2.76 Å) | | Cite: | Oxetane promise delivered: discovery of long acting IDO1 inhibitors suitable for Q3W oral or parenteral dosing
To Be Published
|
|
5KIT
 | |
7RRB
 | | IDO1 IN COMPLEX WITH COMPOUND 9 | | Descriptor: | 3-[4-(6-cyclopropylpyridin-3-yl)phenyl]-N-(4-fluorophenyl)oxetane-3-carboxamide, Indoleamine 2,3-dioxygenase 1 | | Authors: | Lesburg, C.A. | | Deposit date: | 2021-08-09 | | Release date: | 2022-03-16 | | Last modified: | 2022-05-11 | | Method: | X-RAY DIFFRACTION (2.69 Å) | | Cite: | Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing.
J.Med.Chem., 65, 2022
|
|
7RRC
 | | IDO1 IN COMPLEX WITH COMPOUND 14 | | Descriptor: | Indoleamine 2,3-dioxygenase 1, N-(4-fluorophenyl)-3-{4-[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-3-yl]phenyl}oxetane-3-carboxamide | | Authors: | Lesburg, C.A. | | Deposit date: | 2021-08-09 | | Release date: | 2022-03-16 | | Last modified: | 2022-05-11 | | Method: | X-RAY DIFFRACTION (2.18 Å) | | Cite: | Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing.
J.Med.Chem., 65, 2022
|
|
5YAX
 | | Crystal structure of a human neutralizing antibody bound to a HBV preS1 peptide | | Descriptor: | Large envelope protein, SODIUM ION, scFv1 antibody | | Authors: | Liu, X, Zheng, S, Ye, K, Sui, J. | | Deposit date: | 2017-09-02 | | Release date: | 2017-10-11 | | Method: | X-RAY DIFFRACTION (2.5 Å) | | Cite: | A potent human neutralizing antibody Fc-dependently reduces established HBV infections
Elife, 6, 2017
|
|
5IME
 | | Crystal structure of P21-activated kinase 1 (PAK1) in complex with compound 9 | | Descriptor: | 8-(3-aminopropyl)-6-[2-chloro-4-(3-methyl-2-oxopyrazin-1(2H)-yl)phenyl]-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one, Serine/threonine-protein kinase PAK 1 | | Authors: | Li, D, Wang, W. | | Deposit date: | 2016-03-06 | | Release date: | 2016-05-25 | | Last modified: | 2023-09-27 | | Method: | X-RAY DIFFRACTION (2.217 Å) | | Cite: | Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window.
J.Med.Chem., 59, 2016
|
|
4R0U
 | |
4R0P
 | |
